Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ASK: "THE LAST DON" OF MOMENTUM TRADES -- Ignore unavailable to you. Want to Upgrade?

To: Taki who wrote (3193)	1/14/1999 4:23:00 PM
From: MoneyMade	Read Replies (1) \| Respond to of 15987

CYTL shares rocket on HIV vaccine data NEW YORK, Jan 14 (Reuters) - Shares of Cytel Corp. more than tripled in heavy trading Thursday after a Cytel subsidiary said initial data suggested a vaccine it is developing could hold promise for controlling HIV infection. Shares of Cytel jumped $5.75 to $7.75, making the stock one of the leading winners on the Nasdaq stock market. A scientist from Epimmune Inc. told a medical conference in Keystone, Colo., that two separate trials of epitope-based vaccines in macaque monkeys and mice had yielded strong enough results that they would be pursued. In the first study, vaccinated monkeys showed strong immune system responses against an HIV-like virus they were infected with. The monkeys were injected with a virulent strain of SIV, simian immunodeficiency virus. The immune system responses are called CTL, for cytotoxic T-cell. The vaccinated monkeys also showed a quicker immune response when they were infected with the virus. The mouse study showed that Epimmune could also develop a vaccine to work against several different strains of HIV in a single vaccination. The mice showed CTL responses to each of the different epitopes, Epimmune said. Epimmune has struck a deal with G.D. Searle & Co., part of Monsanto Co. (NYSE:MTC - news), to develop immune-stimulating products for the treatment of cancer. Epimmune, a majority-owned subsidiary of Cytel, was not immediately available for further comment.